SUMMARY
Depolarizing neuromuscular blocking drugs administered i.v. do not cross the blood-brain barrier, but may activate the electroencephalogram (EEG) in humans [1, 2] and laboratory animals [3, 4] . This indirect CNS effect is induced by increased proprioceptive afferent activity from intrafusal muscle fibres stimulated by the blocker [5] , by pain arising from muscle damage induced by fasciculation, or by both [2] . Non-depolarizing neuromuscular blocking drugs do not induce such intra-and extra-fusal muscle fibre contractions and have neither direct nor indirect action on the EEG during halothane anaesthesia [1] . The exception to this statement is atracurium which, at physiological pH and temperature, undergoes rapid spontaneous Hofmann degradation and ester hydrolysis [6] , and the major metabolite, laudanosine, possesses convulsant activity [7] .
The introduction of atracurium into clinical practice has thus renewed interest in the CNS actions of laudanosine [8] [9] [10] [11] .
Nitrous oxide has been reported previously to possess both CNS excitant and depressant properties: CNS stimulation is evident as activation of reticular cell firing [12] and excitation of preganglionic sympathetic fibres [13] , and CNS depression as decrease in amplitude of somatosensory evoked responses [14] , prolongation of the latent period of the tail-flick response to radiant heat in rats [15] , suppression of ease of induction of enflurane convulsions [14] , and increase in convulsion threshold in amygdaloidkindled cats [16] . An increase in lignocaine seizure threshold has also been reported in cats [17] .
In the present study, we have attempted to reveal if the CNS effects of laudanosine are augmented or suppressed by nitrous oxide. In our pilot study we noted that the EEG actions of clinical doses of atracurium were subtle and EEG changes per se were not quantitatively measurable [18] . We have measured, therefore, the modification of the convulsion threshold dose of laudanosine by nitrous oxide.
MATERIALS AND METHODS
Male ICR mice weighing 18-30 g were used in the study, which was approved by the Institutional Committee on Animal Research. Seizure thresholds for laudanosine were measured and compared in three groups of mice: control group, not exposed to nitrous oxide, and second and third experimental groups, exposed to nitrous oxide for 20 min and 180 min, respectively.
All experiments were conducted in a Plexiglas anaesthesia box with a polyethylene hood per- mining easy access to the animals. The total volume of the system was 10 litre. The concentration of oxygen in the box was monitored continuously using an oxygen monitor (Ohmeda 5120). After initial flushing with 100% oxygen, a total gas flow of 4 litre min" 1 was delivered from calibrated flowmeters in order to maintain concentrations of 35 % oxygen and 65 % nitrogen (or 65% nitrous oxide) in the box. Mice were studied in groups of three to five. Laudanosine 0.3 % in saline was injected i.p. in doses from 35 to 70 mg kg" 1 with a 5-mg step interval in a volume of 20 ml kg" 1 . Behavioural changes after administration of laudanosine were observed and the number of convulsing mice counted.
After the experiment, all mice were killed with an overdose of pentobarbitone and examined for intra-abdominal blood vessel injury. If this had occurred, the animal was excluded from further analysis.
Air temperature in the box was monitored using a temperature probe (Terumo) and maintained at 24 ± 1 °C with a heating lamp.
Laudanosine (Aldrich Chemical Co. Ltd) in saline was prepared by acidifying with hydrochloric acid 1 mol litre" 1 and buffering to pH 7.0 with sodium bicarbonate 1 mol litre"
1 . The final concentration of 3 mg ml" 1 was adjusted by adding saline. Drug-free solvent solution at the same pH was prepared also and tested in three mice.
The quantal observations of the dose and the associated response (convulsion yes/no) were analysed using an iterative computer program for non-linear regression analysis. By the method of maximum likelihood, the program estimates directly the parameters of the logistic function
where P = probability of a convulsive response; D = dose of laudanosine; s = an exponent defining the slope of the curve; CD 60 = the dose of laudanosine that results in a 50 % probability of response (ED 50 ). In addition to CD 50 and slope, it calculates their respective standard error-a measure of the precision of the parameter estimate. Continuous probability curves of convulsive response vs dose of laudanosine were plotted successively for each of the three data sets. The CD 60 and slope values were compared between the three groups by calculating 95 % confidence limits [19] .
The mean time for onset of convulsions following administration of laudanosine was compared between the three groups by ANOVA [20] . The behavioural changes after i.p. injection of laudanosine were dose-dependent and appeared rapidly. The initial phase was characterized by immobilization, grooming and wet-shake behaviour. This was followed by tremor, jerky movements and, finally, generalized convulsions with hind limb and tail extensions. The convulsions appeared at 201 (39), 202 (43) and 206 (62) s after administration of laudanosine in the control, 20-min and 180-min nitrous oxide pretreated groups, respectively. There were no significant differences between the three groups in the onset time of convulsions. The duration of convulsions and death rate were dose-dependent and, at a dose greater than the 100% convulsive dose in the control group, all mice died. When the pro-convulsive behavioural changes did not culminate in generalized seizure, the mice resumed normal activity after 10-15 min. In seven mice, intra-abdominal bleeding was found and they were excluded from further analysis. A dose of vehicle solution given to three mice did not induce any noticeable changes.
RESULTS
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DISCUSSION
The present study has demonstrated that nitrous oxide had a significant antagonizing effect on the convulsant action of laudanosine. Extrapolation of this finding to the clinical situation requires examination of the nature of the CNS actions of subconvulsive doses of laudanosine. We reported previously that, although all convulsants induced a marked increase in CNS cell firing at the stage of convulsion, the CNS actions of subconvulsive doses differed: for example, enflurane suppressed reticular cell firing at preconvulsive anaesthetic state [12, 21] , while bicuculline, a GABA receptor antagonist, induced activation [22] . Moreover, multiphasic actions of suppression and activation were induced by subconvulsive doses of lignocaine [23] . A convulsant property of nitrous oxide has also been postulated [24] . These reports suggest that the CNS actions of subconvulsive concentrations of laudanosine are not necessarily excitatory. Nevertheless, there are some suggestions from previous reports which indicate an excitatory nature of clinical (subconvulsive) doses of laudanosine, such as "awakening" from anaesthesia [11, 25] , activation of the EEG [26] , and increase in the MAC value for halothane [10] . Therefore, both convulsant and subconvulsant doses of laudanosine are excitatory. This supports extrapolation of the present findings with convulsant doses of laudanosine to the effect on clinical (subconvulsive) doses of laudanosine. To our knowledge, the present study is die first to suggest that nitrous oxide in clinical doses has an antagonistic effect on CNS stimulation by laudanosine. This effect may be attributed to die CNS depressant actions of nitrous oxide.
There is considerable difference between the convulsive doses of laudanosine and those measured following administration of atracurium in clinical practice [4] . In humans receiving infusions of paralysing doses of atracurium, peak plasma concentrations of laudanosine up to 0.81 |ig ml" 1 have been measured at die end of surgery [25] . Much greater plasma concentrations of laudanosine, exceeding 17 \xg ml" 1 , were needed for convulsions to occur in rats [27] and dogs [11] . In the present study, nitrous oxide attenuated the action of convulsive doses of laudanosine and greater suppression may be expected, therefore, in the clinical situation in which the plasma concentrations of laudanosine are much smaller.
Although not statistically significant, there was a tendency for die anticonvulsant action of nitrous oxide to decrease with time. We have reported that acute tolerance develops to several CNS actions of nitrous oxide, such as slowing of EEG [12, 28] , suppression of somatosensory evoked response [14] , antagonism of enflurane [14] and amygdaloid kindling [15] convulsions, but not to the analgesic action [16] . When tolerance de-veloped, the maximum effects of nitrous oxide occurred at 20-30 min, and then subsided gradually at 2-3 h. In the present study the action of nitrous oxide was examined both at a time of maximum effect and after prolonged exposure. The present data indicate that tolerance to the antagonistic effect of nitrous oxide was not significant statistically.
We conclude that nitrous oxide antagonizes the CNS stimulating action of laudanosine, and that the combined use of nitrous oxide and atracurium is an appropriate clinical procedure.
